Pacific Biosciences of California, Inc. is downgraded to Hold with slow commercial adoption & academic funding pressures.

Wall Street analysts expect Pacific Biosciences of California (PACB) to post quarterly loss of -$0.18 per share in its upcoming report, which indicates a year-over-year increase of 10%. Revenues are ...

Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 2.8% in the afternoon session after an analyst at Stephens & Co. raised the price target on the stock while ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.59, demonstrating a -1.85% change from the preceding day's closing price. This change lagged the S&P 500's 0.16% loss on ...